{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:05:59Z","timestamp":1767704759655,"version":"3.48.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:p>This study analysed 32 failed drug development trials and surveyed 56 experts in the field of autoimmune bullous diseases to identify key challenges in bullous pemphigoid and pemphigus research. Clinical trials primarily failed due to unmet efficacy endpoints and recruitment difficulties, with experts highlighting the need to improve endpoint selection and patient enrolment strategies through international collaboration to develop more effective trial designs and advance new therapeutic options.<\/jats:p>","DOI":"10.1093\/bjd\/ljaf366","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:04:38Z","timestamp":1757678678000},"page":"165-167","source":"Crossref","is-referenced-by-count":0,"title":["Navigating challenges in clinical trials for bullous pemphigoid and pemphigus: learnings from the clinical trial graveyard and an international expert survey"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-5654","authenticated-orcid":false,"given":"Eva W H","family":"Korte","sequence":"first","affiliation":[{"name":"Department of Dermatology, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), University of Groningen, University Medical Center Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-1697","authenticated-orcid":false,"given":"Marjolein A J","family":"Hiel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), University of Groningen, University Medical Center Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-9363","authenticated-orcid":false,"given":"Maria\u00a0C","family":"Bolling","sequence":"additional","affiliation":[{"name":"Department of Dermatology, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), University of Groningen, University Medical Center Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7459-1232","authenticated-orcid":false,"given":"Patrick","family":"Dunn","sequence":"additional","affiliation":[{"name":"International Pemphigus & Pemphigoid Foundation , Roseville, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-0199","authenticated-orcid":false,"given":"D\u00e9d\u00e9e\u00a0F","family":"Murrell","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St George Hospital, University of New South Wales , Sydney ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-5369","authenticated-orcid":false,"given":"Victoria P","family":"Werth","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Corporal Michael J. Crescenz Veterans Affairs Medical Center , Philadelphia, PA ,","place":["USA"]},{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6722-3569","authenticated-orcid":false,"given":"Marc","family":"Yale","sequence":"additional","affiliation":[{"name":"International Pemphigus & Pemphigoid Foundation , Roseville, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6035-2863","authenticated-orcid":false,"given":"Phyllis I","family":"Spuls","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amsterdam UMC, Academic Medical Center, University of Amsterdam , Amsterdam ,","place":["the Netherlands"]},{"name":"Amsterdam Public Health, Infection and Immunity, Academic Medical Center, University of Amsterdam , Amsterdam ,","place":["the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-3528","authenticated-orcid":false,"given":"Joost M","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), University of Groningen, University Medical Center Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-3674","authenticated-orcid":false,"given":"Barbara","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Department of Dermatology, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), University of Groningen, University Medical Center Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"2026010607272189200_ljaf366-B1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2026010607272189200_ljaf366-B2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"author":"International Pemphigus & Pemphigoid Foundation","key":"2026010607272189200_ljaf366-B3"},{"key":"2026010607272189200_ljaf366-B4","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.jid.2023.03.1673","article-title":"The importance of patient-focused drug development in pemphigus and pemphigoid","volume":"143","author":"Yale","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2026010607272189200_ljaf366-B5","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jid.2024.02.023","article-title":"Efficacy and safety of rilzabrutinib in pemphigus: PEGASUS phase 3 randomized study","volume":"144","author":"Murrell","year":"2024","journal-title":"J Invest Dermatol"},{"key":"2026010607272189200_ljaf366-B6","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"volume-title":"Endotext","author":"Nicolaides","key":"2026010607272189200_ljaf366-B7"},{"key":"2026010607272189200_ljaf366-B8","doi-asserted-by":"crossref","first-page":"106022","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.106022","article-title":"Home-based interventions may increase recruitment, adherence, and measurement of outcomes in clinical trials of stroke rehabilitation","volume":"30","author":"de Menezes","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf366\/64263552\/ljaf366.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/1\/165\/64263552\/ljaf366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/1\/165\/64263552\/ljaf366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:27:32Z","timestamp":1767702452000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/1\/165\/8253750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,13]]},"published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf366","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,13]]}}}